

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
9 June 2005 (09.06.2005)

PCT

(10) International Publication Number
WO 2005/051895 A1

(51) International Patent Classification:

A61K 31/165 (2006.01) **C07C 237/24** (2006.01)
A61K 31/275 (2006.01) **C07C 255/50** (2006.01)
A61K 31/325 (2006.01) **C07C 271/24** (2006.01)
A61K 31/343 (2006.01) **C07C 323/29** (2006.01)
A61K 31/357 (2006.01) **C07D 207/09** (2006.01)
A61K 31/381 (2006.01) **C07D 295/027** (2006.01)
A61K 31/402 (2006.01) **C07D 307/79** (2006.01)
A61K 31/44 (2006.01) **C07D 313/08** (2006.01)
A61K 31/5377 (2006.01) **C07D 319/18** (2006.01)
C07C 237/20 (2006.01) **C07D 333/08** (2006.01)

Arlesheim (CH). **MAIBAUM, Jürgen, Klaus** [DE/DE];
Lütemannsweg 14/1, 79576 Weil-Haltingen (DE). **SELL-
NER, Holger** [DE/CH]; Keltenstr. 37, CH-4106 Therwil
(CH).

(74) **Agent: GRUBB, Philip**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:

PCT/EP2004/013412

(22) International Filing Date:

25 November 2004 (25.11.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/525,374 26 November 2003 (26.11.2003) US

(71) **Applicant** (*for all designated States except AT, US*): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) **Applicant** (*for AT only*): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) **Inventors/Applicants** (*for US only*): **BAESCHLIN, Daniel, Kaspar** [CH/CH]; In der Schappe 141, CH-4144

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(48) Date of publication of this corrected version:


20 July 2006

(15) Information about Correction:

see PCT Gazette No. 29/2006 of 20 July 2006

[Continued on next page]

(54) Title: ORGANIC COMPOUNDS



(I)

(57) **Abstract:** Disclosed are δ -amino- γ -hydroxy- ω -aryl-alkanoic acid amide compounds of formula (I) and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes,

such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.